by Yu Wing Sze. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2001. / Includes bibliographical references (leaves 119-126). / Abstracts in English and Chinese. / Thesis Committee --- p.ii / Statement --- p.iii / Acknowledgements --- p.iv / Abstract --- p.vi / 摘要 --- p.viii / Table of Contents --- p.x / List of Tables --- p.xvi / List of Figures --- p.xvii / List of Abbreviations --- p.xx / Chapter CHAPTER 1 --- General Introduction --- p.1 / Chapter CHAPTER 2 --- Literature Review --- p.3 / Chapter 2.1 --- Toxoplasma gondii --- p.3 / Chapter 2.1.1 --- Morphology and Life Cycle of T. gondii --- p.3 / Chapter 2.1.2 --- Routes of Transmission --- p.7 / Chapter 2.2 --- Toxoplasmosis --- p.8 / Chapter 2.2.1 --- Influences and Symptoms --- p.8 / Chapter 2.2.2 --- Treatment of Toxoplasmosis --- p.10 / Chapter 2.2.2.1 --- Antitoxoplasma Drugs --- p.10 / Chapter 2.2.2.2 --- Toxoplasma Vaccines --- p.12 / Chapter 2.3 --- Major T. gondii Surface Antigen - P30 --- p.16 / Chapter 2.4 --- Plants as Bioreactors --- p.19 / Chapter 2.4.1 --- Advantages of Plant Bioreactors --- p.19 / Chapter 2.4.2 --- Plant-based Vaccines --- p.20 / Chapter 2.4.2.1 --- VP2 Capsid Protein of Mink Enteritis Virus --- p.21 / Chapter 2.4.2.2 --- Hepatitis B Surface Antigen --- p.21 / Chapter 2.4.2.3 --- Norwalk Virus Capsid Protein --- p.22 / Chapter 2.5 --- Tobacco Expression System --- p.23 / Chapter 2.5.1 --- Transformation Methods --- p.23 / Chapter 2.5.1.1 --- Agrobacterium-mediated Transformation --- p.23 / Chapter 2.5.1.2 --- Direct DNA Uptake --- p.24 / Chapter 2.6 --- Phaseolin and Its Regulatory Sequences --- p.26 / Chapter CHAPTER 3 --- Expression of P30 in Transgenic Tobacco --- p.28 / Chapter 3.1 --- Introduction --- p.28 / Chapter 3.2 --- Materials and Methods --- p.29 / Chapter 3.2.1 --- Chemicals --- p.29 / Chapter 3.2.2 --- Oligos: Primers and Adapters --- p.29 / Chapter 3.2.3 --- Plant Materials --- p.31 / Chapter 3.2.4 --- Bacterial Strains --- p.31 / Chapter 3.2.5 --- Construction of Chimeric Genes --- p.31 / Chapter 3.2.5.1 --- Modification of pET-ASP30ΔPI --- p.32 / Chapter 3.2.5.2 --- Cloning of P30 into Vectors with Different Promoters --- p.38 / Chapter 3.2.5.2.1 --- Cloning ofP30 into Vector with CaMV 35S Promoter --- p.38 / Chapter 3.2.5.2.2 --- Cloning of P30 into Vector with Maize Ubiquitin 1 Promoter --- p.38 / Chapter 3.2.5.2.3 --- Cloning of P30 into Vector with Phaseolin Promoter --- p.38 / Chapter 3.2.5.2.4 --- Cloning of P30 into Vector with Phaseolin Promoter and Phaseolin SP --- p.39 / Chapter 3.2.5.3 --- Cloning of P30 into Agrobacterium Binary Vector pBI121 --- p.44 / Chapter 3.2.6 --- Transformation of Agrobacterium by Electroporation --- p.49 / Chapter 3.2.7 --- "Transformation, Selection and Regeneration of Tobacco " --- p.50 / Chapter 3.2.8 --- GUS Assay --- p.51 / Chapter 3.2.9 --- Synthesis of Single-stranded DIG-labeled DNA Probe --- p.51 / Chapter 3.2.10 --- Extraction of Genomic DNA from Leaves --- p.52 / Chapter 3.2.11 --- PCR of Genomic DNA with P30 Specific Primers --- p.53 / Chapter 3.2.12 --- Southern Blot Analysis of Genomic DNA --- p.53 / Chapter 3.2.13 --- Extraction of Total RNA from Leaves or Developing Seeds --- p.54 / Chapter 3.2.14 --- Reverse Transcription-Polymerase Chain Reaction of Total RNA --- p.55 / Chapter 3.2.15 --- Sequencing of RT-PCR Product --- p.56 / Chapter 3.2.16 --- Northern Blot Analysis of Total RNA --- p.56 / Chapter 3.2.17 --- Extraction of Total Protein from Leaves or Mature Seeds --- p.57 / Chapter 3.2.18 --- Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) --- p.58 / Chapter 3.2.19 --- Purification of 6xHis-tagged Proteins --- p.58 / Chapter 3.2.20 --- Western Blot Analysis of Total Protein --- p.59 / Chapter 3.2.21 --- In vitro Transcription and Translation --- p.60 / Chapter 3.2.21.1 --- Construction of Transcription Vector Containing Chimeric P30 Gene --- p.60 / Chapter 3.2.21.2 --- In vitro Transcription --- p.60 / Chapter 3.2.21.3 --- In vitro Translation --- p.60 / Chapter 3.3 --- Results --- p.65 / Chapter 3.3.1 --- Construction of Chimeric P30 Genes --- p.65 / Chapter 3.3.2 --- "Tobacco Transformation, Selection and Regeneration " --- p.65 / Chapter 3.3.3 --- Detection of GUS Activity --- p.67 / Chapter 3.3.4 --- Detection of P30 Gene in Transgenic Plants --- p.69 / Chapter 3.3.4.1 --- PCR of Genomic DNA --- p.69 / Chapter 3.3.4.2 --- Southern Blot Analysis --- p.72 / Chapter 3.3.5 --- Detection of P30 Transcript in Transgenic Plants --- p.75 / Chapter 3.3.5.1 --- RT-PCR --- p.75 / Chapter 3.3.5.2 --- Sequencing of RT-PCR Product --- p.79 / Chapter 3.3.5.3 --- Northern Blot Analysis --- p.79 / Chapter 3.3.6 --- Detection of P30 Protein in Transgenic Plants --- p.83 / Chapter 3.3.6.1 --- Western Blot Analysis of Total Protein and Ni-NTA Purified Proteins --- p.83 / Chapter 3.3.7 --- In vitro Transcription and Translation --- p.92 / Chapter 3.3.7.1 --- In vitro Transcription --- p.92 / Chapter 3.3.7.2 --- In vitro Translation --- p.92 / Chapter CHAPTER 4 --- Discussion --- p.97 / Chapter 4.1 --- General Conclusion --- p.97 / Chapter 4.2 --- Further Speculations and Investigations --- p.100 / Chapter 4.2.1 --- Other Protein Detection Procedures --- p.100 / Chapter 4.2.2 --- In vitro Transcription and Translation --- p.100 / Chapter 4.2.3 --- Gene Silencing at Transcription and/or Post-transcription Levels --- p.101 / Chapter 4.2.4 --- Gene Silencing at Translation and/or Post-translation Levels --- p.102 / Chapter (A) --- AUG Context Sequence --- p.102 / Chapter (B) --- Codon Usage --- p.103 / Chapter (C) --- N-end Rule --- p.107 / Chapter (D) --- Phaseolin Sorting Signal --- p.107 / Chapter CHAPTER 5 --- Future Perspectives --- p.109 / Chapter 5.1 --- Codon Modification of the P30 Gene --- p.110 / Chapter 5.2 --- Fusion of the P30 Gene with the LRP Gene --- p.117 / Chapter CHAPTER 6 --- Conclusion --- p.118 / References --- p.119

Thesis (Ph. D.)--University of Washington, 2001. / Vita. Includes bibliographical references (leaves 106-125).

Dissertation (Ph.D.)--University of South Florida, 2007. / Title from PDF of title page. Document formatted into pages; contains 147 pages. Includes vita. Includes bibliographical references.

Diss. (sammanfattning) Stockholm : Karol. inst., 2004. / Härtill 4 uppsatser.

Diss. (sammanfattning) Stockholm : Karol. inst., 2003. / Härtill 6 uppsatser. - Titel från omslaget.

Thesis (Ph. D.)--University of Washington, 1997. / Vita. Includes bibliographical references (leaves 97-110).

Thesis (Ph. D.) -- University of Texas Southwestern Medical Center at Dallas, 2003. / Vita. Bibliography: 162-207.

Thesis (Ph.D.)--University of Alabama at Birmingham, 2008. / Title from PDF title page (viewed on Sept. 17, 2009). Includes bibliographical references.

Thesis (Ph. D.)--University of Missouri--Columbia, 2005. / "May 2005." Typescript. Vita. Includes bibliographical references (leaves 139-157). Also issued on the Internet.

Orientadores: Lilian Maria de Castilho, Jeane Eliete Laguila Visentainer / Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas / Made available in DSpace on 2018-08-24T13:14:12Z (GMT). No. of bitstreams: 1 Guelsin_GlauciaAndreiaSoares_D.pdf: 3524338 bytes, checksum: 77312cdc47d244e00235a67d7f52c666 (MD5) Previous issue date: 2014 / Resumo: A síndrome mielosplásica (SMD) correponde a um grupo de distúrbios clonais heterogêneos decorrente de um defeito intrínseco das células progenitoras hematopoéticas, resultando em insuficiência da medula óssea, desencadeando anemia com dependência de transfusões sanguíneas e infecções decorrentes da neutropenia. Embora a terapia transfusional seja segura, muitos desses pacientes correm risco de complicações relacionadas à sobrecarga de ferro e à aloimunização contra antígenos de grupos sanguíneos, que muitas vezes dificulta a busca de sangue compatível para esses pacientes, além estar associada a reações hemolíticas transfusionais tardias e formação de auto-anticorpos. A compatibilidade para antígenos Rh e K tem sido utilizada na tentativa de reduzir a formação de anticorpos em pacientes que recebem transfusões crônicas, mas a fenotipagem estendida, incluindo os antígenos Fya e Jka, também tem sido recomendada. Este estudo teve como objetivos avaliar o perfil transfusional dos pacientes com SMD, propor um protocolo de compatibilidade molecular para seleção de sangue fenótipo compatível e avaliar uma possível associação dos alelos HLA com a susceptibilidade ou proteção a aloimunização eritrocitária. Foram analisados 61 pacientes portadores de SMD, sendo 18 pacientes não transfundidos e 43 pacientes submetidos à terapia transfusional com e sem formação de anticorpos. Realizamos genotipagem para os alelos de grupos sanguíneos RHD, RHCE, FY, DO, CO, DI, SC, GYPA, GYPB, LU, KEL, JK e LW e para os alelos HLA classe I e classe II nas amostras dos pacientes e comparamos os resultados com grupos- controle. Com relação ao perfil transfusional dos pacientes estudados, a maioria recebe transfusões sanguíneas regulares e 44% encontra-se aloimunizada. Os principais aloanticorpos detectados foram contra antígenos Rh e K. Verificamos que a genotipagem é superior a fenotipagem para determinação dos antígenos de grupos sanguíneos e que a compatibilidade molecular para Rh e K seria suficiente para evitar a aloimunização eritrocitária na maioria dos pacientes. Nossos resultados também mostraram uma associação entre o alelo HLA-DRB1*13 e a proteção à aloimunização contra antígenos de grupos sanguíneos em pacientes com SMD / Abstract: The myelodysplastic syndrome (MDS) is a group of heterogeneous clonal disorder caused by an intrinsic stem cell defect with propensity to the bone marrow failure that results in the transfusion dependence and neutropenic infection. Although blood transfusion is generally safe, many of those patients are at risk of transfusion-related complications such as iron overload and RBC alloimmunization that often makes finding compatible RBC products difficult and is also associated with delayed hemolytic transfusion reactions (DHTRs) and autoantibody formation. Matching for Rh and K antigens has been used in an attempt to reduce antibody formation in patients receiving chronic transfusions but an extended phenotyping matching including Fya and Jka antigens has also been recommended. This study was aimed to identify the transfusion profile of the patients with myelodysplastic syndrome (MDS), an efficient transfusion protocol of genotype matching and a possible association of HLA class alleles with susceptibility or protection to RBC alloimmunization. We evaluated 61 patients with MDS, 18 not transfused and 43 undergoing transfusion therapy with and without antibody formation. We performed genotyping for RHD, RHCE, FY, DO, CO, DI, SC, GYPA, GYPB, LU, KEL, JK e LW and for HLA class I and class II alleles in the patient DNA samples and compared the results with a control group. We verified that the majority of patients have regular transfusions and 44% are alloimmunized to RBC antigens. Blood group genotyping was superior to phenotyping to determine the antigen profile in those patients and molecular matching for Rh and K would be enough for most of the patients. Our results also showed a significant association of HLA-DRB1*13 with protection to RBC alloimmunization in patients with MDS / Doutorado / Clinica Medica / Doutora em Clínica Médica